Biosimilars for Omvoh: Are Any Available Yet?

There are no FDA-approved biosimilars for Omvoh in the United States as of August 10, 2026. The FDA list contains no mirikizumab product referencing Omvoh. Because Omvoh is an inflammatory bowel disease biologic, searches may surface similar interleukin-23 drugs, trial programs, or general biosimilar information. None of those results creates an approved Omvoh biosimilar.

Are any biosimilars for Omvoh available?

The FDA Purple Book record for Omvoh identifies mirikizumab-mrkz as the proper name and Omvoh as a 351(a) reference product from Eli Lilly. A future biosimilar would receive its own 351(k) license and a distinct suffix attached to mirikizumab. FDA's current product directory shows no such approval.

Omvoh also has no generic version. The FDA patient guide explains that biologics come from living sources and are evaluated differently from conventional generic drugs. A medicine with a similar mechanism or the same disease indication is an alternative therapy. It becomes an Omvoh biosimilar only after FDA reviews comparative evidence and licenses it with Omvoh as the reference product.

What Omvoh is and how it is given

Omvoh is mirikizumab-mrkz, an interleukin-23 antagonist. The current prescribing information includes adults with moderately to severely active ulcerative colitis and Crohn's disease. The treatment uses intravenous induction and subcutaneous maintenance, so patients may encounter an infusion order followed by a prescription for prefilled pens or syringes.

The FDA trial snapshot describes the original ulcerative colitis approval and the intravenous-to-subcutaneous treatment pattern studied in LUCENT-1 and LUCENT-2. A three-year LUCENT-3 analysis reported longer-term outcomes among patients continuing mirikizumab. Those studies support the reference drug's clinical record and do not represent comparison studies for an Omvoh biosimilar.

For identification, compare every order with the active ingredient mirikizumab-mrkz. The infusion record and maintenance shipment should also show the prescribed strength and route. A change in packaging or delivery device can occur within the Omvoh brand. The FDA product name and suffix reveal whether the medication remains the reference product described in the label.

Other interleukin-23 drugs are separate products

IBD treatment now includes several medicines that affect interleukin-23 signaling. They have different active ingredients, FDA applications, labels, doses, and devices. A health plan may describe one as an alternative to Omvoh, while that request changes the therapy itself. The FDA biosimilar review process requires high similarity to a named reference product and no clinically meaningful differences in safety, purity, or potency.

Changing from Omvoh infusion to Omvoh injection is also distinct from biosimilar substitution. It follows the induction and maintenance sequence in the Omvoh label. Review the full brand name, mirikizumab suffix, route, strength, and device whenever a new order or shipment arrives. Those fields identify the medication more reliably than broad terms such as "similar," "preferred," or "equivalent."

Insurance implications while Omvoh has no biosimilar

The absence of an approved Omvoh biosimilar prevents a plan from selecting a direct mirikizumab biosimilar substitute today. Plans can still impose prior authorization, specialty-pharmacy requirements, infusion-site rules, or preferred-therapy criteria. The Crohn's & Colitis Foundation recommends asking which exact medication is covered, when a change begins, where it will be supplied, what it will cost, and how to appeal.

Intravenous induction may be processed through the medical benefit, while maintenance injections may be processed through the pharmacy benefit. CMS publishes Part B payment material for clinician-administered biological products, and commercial coverage varies. Confirm both phases with the insurer, including the authorized facility, specialty pharmacy, approval dates, dose, deductible, copay, coinsurance, and any assistance-program restrictions.

Ask the insurer to state any preferred alternative by full brand and active-ingredient name. If the proposed product uses another active ingredient, send the policy and deadline to the gastroenterology office for clinical review. If the issue concerns the Omvoh supplier or authorization, record the plan's case number and the pharmacy's inventory response. Include the next dose date in every follow-up message.

How to monitor future Omvoh biosimilar approvals

Use the current FDA biosimilar product list and Purple Book Omvoh record. A U.S.-approved product should have a proprietary name, a mirikizumab suffix, a 351(k) license, an applicant, an approval date, and an explicit Omvoh reference. Approval, launch, formulary placement, and pharmacy inventory may occur at different times.

As of August 10, 2026, the correct answer to "biosimilars for Omvoh" is that none are FDA-approved. A new device, a transition from infusion to injection, or an insurer-preferred interleukin-23 medicine describes a different event. Exact product names and FDA records keep the distinction clear as the market develops.

Recheck the FDA pages when a news story or coverage letter announces a new product. Search by both Omvoh and mirikizumab because a biosimilar will have its own brand and suffix. Then ask the prescribing office and supplier whether the approved presentation matches the IBD dose and is commercially available. These steps separate regulatory approval from stocking and formulary decisions.